Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

the patient's thigh. From this muscle specimen, autologous myoblasts (muscle stem cells) are then isolated, grown using Bioheart's proprietary cell-culturing process, and injected directly into the scar tissue of the patient's heart. The myoblast cells are delivered via an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The myoblast-based muscle formation in the newly populated regions of scar tissue are intended to improve cardiac function by helping the heart muscle beat more efficiently.

ABOUT BIOHEART, INC.

Bioheart, Inc. (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more informat
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Astellas ... director of Business Communications & Advocacy, Urology in ... Business Communications & Advocacy Margaret Long. In this role, ... to urology to patient and advocacy organizations, as ... on key strategic initiatives. Noland,s appointment is the ...
(Date:9/16/2014)... 16, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... commencing an underwritten registered public offering of shares ... are being offered by Aratana Therapeutics. ... joint book-running managers for the offering.  ...
(Date:9/16/2014)... 16, 2014 /PRNewswire-iReach/ -- Dan York has ... manufacturer of the RTD ® Advanced Wound Care ... its sales presence in the U.S. Under York,s leadership, ... direct field sales representatives in new sales territories that ... to add up to 20 sales representatives in major ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... June 2 Today In the Face of ... help pain management advocates expand their outreach efforts through popular ... to social media applications, such as Facebook, and walks users ... communication vehicles. Topics include "An Overview of Social Media," "Advocacy ...
... , JERUSALEM , June ... of oral drug delivery systems, announced,today that its subsidiary Oramed ... Ltd. ("Laser Detect"), an Israeli company listed on,the Tel Aviv ... be,called Entera Bio Ltd. ("Entera"). Under the terms of the ...
Cached Medicine Technology:In the Face of Pain® Offers Social Media 101 for Pain Management Advocates 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3
(Date:9/17/2014)... 2014 As kids settle back ... top of mind for parents, teachers and coaches. ... about concussions and an informative video, Pediatric Concussions: ... coaches and teachers to detect, talk about and ... a pediatric orthopedic surgeon, I witness youth sports ...
(Date:9/17/2014)... 17, 2014 ICS Learning Group, Inc. ... Excellence in Training for the Best Use of Games ... on an online operational safety training module that ICS ... operation. Using an approach that combined realistic 3D ... that was similar to a video game, including competition ...
(Date:9/17/2014)... CA / MANILA, PHILIPPINES (PRWEB) September 17, 2014 ... providing Managed Operations and Business Process Outsourcing (BPO) services ... joined the firm as the Senior Vice President – ... U.S.. , Cary Weltken is a 15 year ... a wealth of experience in helping companies, ranging in ...
(Date:9/17/2014)... Freeslate, Inc. , the ... drug development, today announced that Baylor University acquired ... System to both support Baylor research interests and ... high throughput system is expected to significantly accelerate ... optimization for small molecule organic chemistry. , The ...
(Date:9/17/2014)... 17, 2014 Luxury Barber, the purveyor ... their newest addition to the Regenepure family: The Regenepure ... with nourishing and beneficial ingredients including biotin, silk proteins, ... with ample moisture, while also encouraging volume and shine. ... to complement the Regenepure DR doctor recommended ...
Breaking Medicine News(10 mins):Health News:Video Helps Kids and Adults Talk About Concussion Recognition and Treatment 2Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:MicroSourcing Appoints New Senior Vice President of North America 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Luxury Barber Adds New Regenepure Biotin Conditioner to Their Selection of Grooming Products 2
... today at 10:00 a.m. EST by calling, ... the Web at: http://www.airproducts.com/Invest/financialnews/EarningsReleases.htm ... Products,(NYSE: APD ) today reported net income of ... for its fiscal first quarter ended December 31,2007. Net ...
... DEERFIELD, Ill., Jan. 23 Astellas Pharma Inc. ... (FDA) has approved their,Supplemental New Drug Application (sNDA) ... for Injection in the treatment of patients,with Candidemia, ... approved in 2005 for the treatment of patients ...
... NDA Approval for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), ... for the Prevention ... Preterm Birth in Singleton Pregnancies, ST. LOUIS, Jan. ... specialty pharmaceutical company that,develops, manufactures, acquires and markets technology-differentiated,branded ...
... Advanced Therapy, HOLLYWOOD, Fla., Jan. 22 ... clot-busting drugs may succeed with more,advanced therapies that ... data being presented at the 20th annual International ... fail to improve with standard intravenous (IV),stroke therapy ...
... Calif., Jan. 22 Coherent, Inc.,(Pink Sheets: COHR), today ... market close and host a live webcast to discuss,its ... 7,2008 at 4:30 p.m. ET., The call will ... accessed,at either http://www.coherent.com/Investors/ or http://www.earnings.com .,For ...
... boy,s body is taken to the cleaners with the hospital ... Worth,couple has filed a lawsuit against Huguley Memorial Medical Center ... cleaners with the,hospital laundry., On July 8, 2007, Kourtney ... did not survive and his body was taken to the,hospital ...
Cached Medicine News:Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 2Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 3Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 4Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 5Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 6Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 7Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 8Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 9Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 10Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 11Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 12Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 13Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 14Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 15Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 16Health News:FDA Approves Additional Indication for Astellas' MYCAMINE(R) 2Health News:FDA Approves Additional Indication for Astellas' MYCAMINE(R) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5Health News:Stroke Undertreated 2Health News:Stroke Undertreated 3Health News:A Fort Worth Couple Sues Huguley Memorial Medical Center 2
200 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Inquire...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
Medicine Products: